You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Article info

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma

Authors

  • Niklas Klümper Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, GermanyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Damian J Ralser Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Obstetrics and Gynecology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Romina Zarbl Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Katrin Schlack Department of Urology, University Hospital Münster, Münster, Germany PubMed articlesGoogle scholar articles
  • Andres Jan Schrader Department of Urology, University Hospital Münster, Münster, Germany PubMed articlesGoogle scholar articles
  • Marc Rehlinghaus Department of Urology, University Hospital Düsseldorf, Medical Faculty, Düsseldorf, GermanyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Düsseldorf, Germany PubMed articlesGoogle scholar articles
  • Michèle J Hoffmann Department of Urology, University Hospital Düsseldorf, Medical Faculty, Düsseldorf, GermanyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Düsseldorf, Germany PubMed articlesGoogle scholar articles
  • Günter Niegisch Department of Urology, University Hospital Düsseldorf, Medical Faculty, Düsseldorf, GermanyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Düsseldorf, Germany PubMed articlesGoogle scholar articles
  • Annemarie Uhlig Department of Urology, University Hospital Göttingen, Göttingen, Germany PubMed articlesGoogle scholar articles
  • Lutz Trojan Department of Urology, University Hospital Göttingen, Göttingen, Germany PubMed articlesGoogle scholar articles
  • Julie Steinestel Department of Urology, University Hospital Augsburg, Augsburg, Germany PubMed articlesGoogle scholar articles
  • Konrad Steinestel Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Ulm, Germany PubMed articlesGoogle scholar articles
  • Ralph M Wirtz STRATIFYER Molecular Pathology GmbH, Cologne, GermanyInstitute of Pathology, St. Elisabeth Hospital, Cologne, Germany PubMed articlesGoogle scholar articles
  • Danijel Sikic Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, GermanyDepartment of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Markus Eckstein Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, GermanyInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Glen Kristiansen Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyInstitute of Pathology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Marieta Toma Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyInstitute of Pathology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Michael Hölzel Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, GermanyCenter for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany PubMed articlesGoogle scholar articles
  • Manuel Ritter Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Sebastian Strieth Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Jörg Ellinger Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  • Dimo Dietrich Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, GermanyDepartment of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to PD Dr. rer. nat. Dimo Dietrich; dimo.dietrich{at}gmail.com
View Full Text

Citation

Klümper N, Ralser DJ, Zarbl R, et al
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer 2021;9:e002949. doi: 10.1136/jitc-2021-002949

Publication history

  • Accepted July 29, 2021
  • First published August 26, 2021.
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.